About Alkermes (NASDAQ:ALKS)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes. It is also developing Aripiprazole Lauroxil NanoCrystal Dispersion; ALKS 5461 for the treatment of depressive disorder; ALKS 3831 to treat schizophrenia; BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; and ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; development and license agreement with AstraZeneca plc; and license and collaboration agreement with Biogen MA Inc. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ALKS
CUSIPG0176710
Phone353-1772-8000
Debt
Debt-to-Equity Ratio0.23%
Current Ratio2.78%
Quick Ratio2.46%
Price-To-Earnings
Trailing P/E Ratio-119.11
Forward P/E Ratio-77.32
P/E GrowthN/A
Sales & Book Value
Annual Sales$903.37 million
Price / Sales7.56
Cash Flow$0.2689 per share
Price / Cash163.88
Book Value$7.82 per share
Price / Book5.64
Profitability
EPS (Most Recent Fiscal Year)($0.37)
Net Income$-157,940,000.00
Net Margins-17.48%
Return on Equity-4.32%
Return on Assets-2.97%
Miscellaneous
Employees2,000
Outstanding Shares155,000,000
Alkermes (NASDAQ:ALKS) Frequently Asked Questions
What is Alkermes' stock symbol?
Alkermes trades on the NASDAQ under the ticker symbol "ALKS."
How were Alkermes' earnings last quarter?
Alkermes (NASDAQ:ALKS) issued its quarterly earnings results on Wednesday, February, 14th. The company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of ($0.01) by $0.32. The firm had revenue of $275.37 million for the quarter, compared to analysts' expectations of $251.23 million. Alkermes had a negative return on equity of 4.32% and a negative net margin of 17.48%. The business's revenue for the quarter was up 29.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.02 EPS. View Alkermes' Earnings History.
When is Alkermes' next earnings date?
What guidance has Alkermes issued on next quarter's earnings?
Alkermes updated its FY18 earnings guidance on Wednesday, February, 14th. The company provided earnings per share (EPS) guidance of ($0.23-0.03) for the period, compared to the Thomson Reuters consensus estimate of $0.73. The company issued revenue guidance of $975 million-1.025 billion, compared to the consensus revenue estimate of $1.01 billion.
What price target have analysts set for ALKS?
11 Wall Street analysts have issued 1 year target prices for Alkermes' shares. Their predictions range from $45.00 to $81.00. On average, they anticipate Alkermes' stock price to reach $60.6364 in the next twelve months. View Analyst Ratings for Alkermes.
What are Wall Street analysts saying about Alkermes stock?
Here are some recent quotes from research analysts about Alkermes stock:
- 1. According to Zacks Investment Research, "Alkermes' Vivitrol and Aristada are primary growth drivers. 2018 is expected to be a transformative year for Alkermes’ development pipeline, with key events being- the phase III data readout for ALKS 3831 in schizophrenia, submission of the BIIB098 (ALKS 8700) NDA and phase I data read-out for ALKS 4230.In April 2018, the FDA accepted for review the new drug application (NDA) for ALKS 5461 for the treatment of major depressive disorder (“MDD”). The FDA had initially issued a Refusal to File letter on Mar 30 for the candidate stating that the NDA did not have enough evidence for the oral medication to work. The company also expects to expand its field sales team by about 200 sales representatives in mid 2018 as it prepares for the potential launch of ALKS 5461 in early 2019. However, Alkermes is highly dependent on manufacturing and/or royalty revenues on sales of products that are commercialized by the company's partners" (4/20/2018)
- 2. Cantor Fitzgerald analysts commented, "FDA response looks like someone may not have been listening. The nature of the FDA response to ALKS stands in stark contrast to a comment by the CEO on the 2Q17 results conference call, Earlier this week, we passed a major milestone with the outcome of our pre-NDA meeting with the FDA, which resulted in an agreement on our NDA submission content and timing." We generally take with a grain of salt any management comments that FDA meetings went well" or were productive" but we believe investors may have been led to believe that the FDA viewed the ALKS 5461 data as potentially adequate for approval. That the FDA evidently has asked for additional clinical studies strongly calls into question such an assumption, in our opinion." (4/2/2018)
- 3. Cowen Inc analysts commented, "ALKS reported Q1:17 results which came in below expectations." (4/28/2017)
Who are some of Alkermes' key competitors?
Some companies that are related to Alkermes include Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), Ono Pharmaceutical (OPHLF), Nektar Therapeutics (NKTR), Merck Group (MKGAF), Genmab As (GNMSF), Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ) and BeiGene (BGNE).
Who are Alkermes' key executives?
Alkermes' management team includes the folowing people:
- Mr. Richard F. Pops, Chairman & CEO (Age 56)
- Mr. Shane Martin Cooke, Director (Age 56)
- Dr. Floyd E. Bloom, Co-Founder & Director (Age 81)
- Mr. James M. Frates, Sr. VP, CFO & Treasurer (Age 51)
- Ms. Kathryn L. Biberstein, Chief Admin. Officer, Chief Compliance Officer, Chief Risk Officer & Exec. VP (Age 59)
Has Alkermes been receiving favorable news coverage?
Press coverage about ALKS stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alkermes earned a news sentiment score of 0.13 on Accern's scale. They also assigned news headlines about the company an impact score of 45.98 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Alkermes?
Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alkermes' stock price today?
One share of ALKS stock can currently be purchased for approximately $44.07.
How big of a company is Alkermes?
Alkermes has a market capitalization of $7.00 billion and generates $903.37 million in revenue each year. The company earns $-157,940,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Alkermes employs 2,000 workers across the globe.
How can I contact Alkermes?
Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]
MarketBeat Community Rating for Alkermes (ALKS)
MarketBeat's community ratings are surveys of what our community members think about Alkermes and other stocks. Vote "Outperform" if you believe ALKS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALKS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Alkermes (NASDAQ:ALKS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Alkermes in the last 12 months. Their average twelve-month price target is $60.6364, suggesting that the stock has a possible upside of 37.59%. The high price target for ALKS is $81.00 and the low price target for ALKS is $45.00. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.36 | 2.36 | 2.45 | 2.45 |
| Ratings Breakdown: | 0 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $60.6364 | $63.90 | $63.5455 | $63.5455 |
| Price Target Upside: | 37.59% upside | 13.00% upside | 26.18% upside | 27.47% upside |
Alkermes (NASDAQ:ALKS) Consensus Price Target History
Alkermes (NASDAQ:ALKS) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Alkermes (NASDAQ:ALKS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Alkermes (NASDAQ ALKS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.51%
Alkermes (NASDAQ ALKS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/2/2018 | Paul J Mitchell | Director | Sell | 1,000 | $46.75 | $46,750.00 | 8,000 |  |
| 3/1/2018 | Paul J Mitchell | Director | Sell | 1,000 | $57.04 | $57,040.00 | 9,000 | |
| 2/16/2018 | Mark Stejbach | SVP | Sell | 10,880 | $70.50 | $767,040.00 | 54,893 | |
| 2/2/2018 | Shane Cooke | Insider | Sell | 72,793 | $60.55 | $4,407,616.15 | 147,501 | |
| 2/1/2018 | Paul J Mitchell | Director | Sell | 1,000 | $56.77 | $56,770.00 | 9,000 | |
| 1/29/2018 | Shane Cooke | Insider | Sell | 3,300 | $60.00 | $198,000.00 | 76,408 | |
| 1/26/2018 | Shane Cooke | Insider | Sell | 1,700 | $60.02 | $102,034.00 | 76,408 | |
| 1/11/2018 | Shane Cooke | Insider | Sell | 6,207 | $60.22 | $373,785.54 | 80,915 | |
| 1/2/2018 | Paul J Mitchell | Director | Sell | 1,000 | $54.99 | $54,990.00 | 9,000 | |
| 12/29/2017 | Iain Michael Brown | SVP | Sell | 10,652 | $54.81 | $583,836.12 | | |
| 12/29/2017 | Iain Michael Brown | CAO | Sell | 10,652 | $54.81 | $583,836.12 | 16,943 | |
| 12/20/2017 | Laurie Keating | SVP | Sell | 6,249 | $121.20 | $757,378.80 | | |
| 12/1/2017 | Paul J Mitchell | Director | Sell | 1,000 | $51.98 | $51,980.00 | 9,000 | |
| 11/29/2017 | James M Frates | SVP | Sell | 20,932 | $50.51 | $1,057,275.32 | 164,971 | |
| 11/8/2017 | James M. Frates | SVP | Sell | 20,932 | $47.58 | $995,944.56 | | |
| 11/2/2017 | Richard F Pops | Director | Sell | 50,000 | $48.87 | $2,443,500.00 | | |
| 11/1/2017 | Michael J Landine | SVP | Sell | 15,000 | $48.71 | $730,650.00 | 178,693 | |
| 10/2/2017 | Paul J Mitchell | Director | Sell | 1,500 | $50.64 | $75,960.00 | | |
| 9/11/2017 | Kathryn L Biberstein | CAO | Sell | 13,566 | $51.29 | $695,800.14 | 70,455 | |
| 9/1/2017 | Paul J Mitchell | Director | Sell | 1,500 | $50.77 | $76,155.00 | 9,500 | |
| 8/1/2017 | Paul J Mitchell | Director | Sell | 1,500 | $54.91 | $82,365.00 | 9,500 | |
| 7/3/2017 | Paul J Mitchell | Director | Sell | 1,500 | $58.11 | $87,165.00 | 9,500 | |
| 6/8/2017 | Shane Cooke | Insider | Sell | 10,000 | $60.33 | $603,300.00 | 84,708 | |
| 6/1/2017 | Paul J Mitchell | Director | Sell | 1,500 | $57.49 | $86,235.00 | 9,500 | |
| 5/24/2017 | Richard F Pops | Director | Sell | 25,000 | $57.42 | $1,435,500.00 | 649,137 | |
| 5/18/2017 | Michael J Landine | SVP | Sell | 10,000 | $57.23 | $572,300.00 | 167,370 | |
| 5/17/2017 | Richard F Pops | Director | Sell | 50,000 | $58.19 | $2,909,500.00 | 680,406 | |
| 5/11/2017 | Michael J Landine | SVP | Sell | 10,000 | $57.01 | $570,100.00 | 172,370 | |
| 5/10/2017 | Richard F Pops | Director | Sell | 25,000 | $57.29 | $1,432,250.00 | 655,406 | |
| 5/4/2017 | Shane Cooke | Insider | Sell | 6,500 | $60.05 | $390,325.00 | 78,448 | |
| 4/17/2017 | Elliot Ehrich | CMO | Sell | 10,000 | $56.60 | $566,000.00 | 65,071 | |
| 4/3/2017 | Kathryn L Biberstein | CAO | Sell | 15,000 | $57.68 | $865,200.00 | 69,904 | |
| 4/3/2017 | Paul J Mitchell | Director | Sell | 1,500 | $58.31 | $87,465.00 | 9,500 | |
| 3/29/2017 | Shane Cooke | Insider | Sell | 2,070 | $60.00 | $124,200.00 | 72,148 | |
| 3/23/2017 | Shane Cooke | Insider | Sell | 6,030 | $60.01 | $361,860.30 | 74,948 | |
| 3/21/2017 | Shane Cooke | Insider | Sell | 1,900 | $60.09 | $114,171.00 | 72,048 | |
| 3/20/2017 | Shane Cooke | Insider | Sell | 300 | $60.00 | $18,000.00 | 72,048 | |
| 3/15/2017 | Elliot Ehrich | CMO | Sell | 11,000 | $56.74 | $624,140.00 | 66,071 | |
| 3/7/2017 | James M Frates | SVP | Sell | 25,000 | $59.08 | $1,477,000.00 | 144,053 | |
| 3/2/2017 | Robert A Breyer | Director | Sell | 4,000 | $60.00 | $240,000.00 | 7,156 | |
| 3/2/2017 | Shane Cooke | Insider | Sell | 20,000 | $60.00 | $1,200,000.00 | 73,068 | |
| 3/1/2017 | Paul J Mitchell | Director | Sell | 1,500 | $57.06 | $85,590.00 | 9,500 | |
| 2/16/2017 | Elliot Ehrich | CMO | Sell | 11,000 | $56.68 | $623,480.00 | 49,657 | |
| 2/1/2017 | Paul J Mitchell | Director | Sell | 1,500 | $54.45 | $81,675.00 | 9,500 | |
| 1/17/2017 | Elliot Ehrich | CMO | Sell | 11,983 | $54.32 | $650,916.56 | 62,640 | |
| 1/9/2017 | Mark Stejbach | SVP | Sell | 547 | $60.27 | $32,967.69 | 34,662 | |
| 1/9/2017 | Shane Cooke | Insider | Sell | 550 | $60.27 | $33,148.50 | 64,494 | |
| 1/6/2017 | Elliot Ehrich | CMO | Sell | 10,000 | $59.44 | $594,400.00 | 60,140 | |
| 1/6/2017 | Mark Stejbach | SVP | Sell | 9,453 | $60.05 | $567,652.65 | 36,615 | |
| 1/6/2017 | Shane Cooke | Insider | Sell | 9,450 | $60.06 | $567,567.00 | 66,487 | |
| 1/4/2017 | Robert A Breyer | Director | Sell | 4,000 | $60.00 | $240,000.00 | 11,156 | |
| 1/3/2017 | David Joseph Gaffin | SVP | Sell | 2,500 | $55.40 | $138,500.00 | 27,207 | |
| 1/3/2017 | Paul J Mitchell | Director | Sell | 1,500 | $55.40 | $83,100.00 | 9,500 | |
| 12/16/2016 | Gordon G Pugh | COO | Sell | 21,458 | $57.65 | $1,237,053.70 | 37,277 | |
| 12/15/2016 | Elliot Ehrich | CMO | Sell | 5,000 | $55.99 | $279,950.00 | 57,640 | |
| 12/14/2016 | James M Frates | SVP | Sell | 25,000 | $54.73 | $1,368,250.00 | 127,342 | |
| 12/12/2016 | Elliot Ehrich | CMO | Sell | 16,983 | $55.15 | $936,612.45 | 64,623 | |
| 12/8/2016 | Kathryn L Biberstein | CAO | Sell | 14,145 | $56.13 | $793,958.85 | 43,687 | |
| 12/7/2016 | James M. Frates | SVP | Sell | 23,731 | $56.28 | $1,335,580.68 | | |
| 12/1/2016 | Kathryn L Biberstein | CAO | Sell | 15,000 | $56.13 | $841,950.00 | 38,687 | |
| 11/30/2016 | Michael J Landine | SVP | Sell | 10,000 | $57.51 | $575,100.00 | 165,659 | |
| 11/29/2016 | Richard F Pops | Director | Sell | 30,000 | $56.98 | $1,709,400.00 | 638,962 | |
| 11/22/2016 | Richard F Pops | Director | Sell | 30,000 | $58.66 | $1,759,800.00 | 638,962 | |
| 10/4/2016 | Paul J Mitchell | Director | Sell | 2,000 | $47.42 | $94,840.00 | 10,000 | |
| 9/22/2016 | Elliot Ehrich | CMO | Sell | 5,000 | $50.83 | $254,150.00 | 46,477 | |
| 9/16/2016 | Elliot Ehrich | CMO | Sell | 5,000 | $48.87 | $244,350.00 | 50,311 | |
| 9/6/2016 | David Joseph Gaffin | SVP | Sell | 2,382 | $45.92 | $109,381.44 | 22,816 | |
| 9/6/2016 | Elliot Ehrich | CMO | Sell | 10,000 | $46.02 | $460,200.00 | 55,311 | |
| 9/6/2016 | Iain Michael Brown | CAO | Sell | 29,976 | $45.92 | $1,376,497.92 | 25,696 | |
| 9/6/2016 | Paul J Mitchell | Director | Sell | 2,000 | $45.92 | $91,840.00 | 10,000 | |
| 8/4/2016 | Paul J Mitchell | Director | Sell | 2,000 | $49.48 | $98,960.00 | 10,000 | |
| 7/27/2016 | Elliot Ehrich | CMO | Sell | 35,199 | $51.95 | $1,828,588.05 | 46,111 | |
| 7/5/2016 | Paul J Mitchell | Director | Sell | 2,000 | $45.81 | $91,620.00 | 10,000 | |
| 6/6/2016 | Paul J Mitchell | Director | Sell | 2,000 | $44.98 | $89,960.00 | 10,000 | |
| 5/4/2016 | Paul J Mitchell | Director | Sell | 2,000 | $38.60 | $77,200.00 | 10,000 | |
| 4/20/2016 | Michael J Landine | SVP | Sell | 16,875 | $41.09 | $693,393.75 | 159,419 | |
| 4/19/2016 | Richard F Pops | CEO | Sell | 18,750 | $40.15 | $752,812.50 | 595,247 | |
| 4/18/2016 | Iain Michael Brown | CAO | Sell | 5,368 | $39.27 | $210,801.36 | 51,822 | |
| 4/13/2016 | Elliot Ehrich | CMO | Sell | 11,698 | $37.66 | $440,546.68 | 52,642 | |
| 4/12/2016 | Richard F Pops | CEO | Sell | 25,000 | $37.79 | $944,750.00 | 601,497 | |
| 4/4/2016 | Paul J Mitchell | Director | Sell | 2,000 | $35.65 | $71,300.00 | 10,000 | |
| 3/22/2016 | Richard F Pops | CEO | Sell | 25,000 | $31.77 | $794,250.00 | 601,497 | |
| 3/15/2016 | Richard F Pops | CEO | Sell | 25,000 | $31.40 | $785,000.00 | 581,307 | |
| 3/4/2016 | Paul J Mitchell | Director | Sell | 2,000 | $32.80 | $65,600.00 | 10,000 | |
| 3/3/2016 | David W Anstice | Director | Buy | 5,000 | $32.87 | $164,350.00 | 15,000 | |
| 2/4/2016 | Paul J. Mitchell | Director | Sell | 2,000 | $32.81 | $65,620.00 | 8,000 | |
| 1/4/2016 | Robert A Breyer | Director | Sell | 2,000 | $77.33 | $154,660.00 | 35,156 | |
| 12/28/2015 | Mark Stejbach | insider | Sell | 10,000 | $80.24 | $802,400.00 | 19,564 | |
| 12/23/2015 | Shane Cooke | insider | Sell | 18,000 | $77.23 | $1,390,140.00 | 50,240 | |
| 12/7/2015 | Michael J. Landine | SVP | Sell | 3,750 | $73.02 | $273,825.00 | 141,324 | |
| 12/7/2015 | Richard F. Pops | CEO | Sell | 37,500 | $72.06 | $2,702,250.00 | 553,497 | |
| 12/1/2015 | Mark Stejbach | insider | Sell | 18,000 | $72.18 | $1,299,240.00 | 19,564 | |
| 12/1/2015 | Michael J. Landine | SVP | Sell | 10,000 | $72.18 | $721,800.00 | 141,324 | |
| 12/1/2015 | Richard F. Pops | CEO | Sell | 50,000 | $72.29 | $3,614,500.00 | 553,497 | |
| 12/1/2015 | Robert A Breyer | Director | Sell | 2,000 | $73.46 | $146,920.00 | 37,156 | |
| 11/23/2015 | Shane Cooke | insider | Sell | 18,000 | $72.62 | $1,307,160.00 | 50,240 | |
| 11/2/2015 | Mark Stejbach | insider | Sell | 18,000 | $72.06 | $1,297,080.00 | 19,964 | |
| 11/2/2015 | Robert A Breyer | Director | Sell | 2,000 | $71.80 | $143,600.00 | 39,156 | |
| 10/29/2015 | Iain Michael Brown | CAO | Sell | 10,822 | $69.99 | $757,431.78 | 38,689 | |
| 10/23/2015 | Shane Cooke | insider | Sell | 18,000 | $62.03 | $1,116,540.00 | 50,240 | |
| 10/13/2015 | James M. Frates | CFO | Sell | 20,000 | $59.78 | $1,195,600.00 | 51,357 | |
| 10/2/2015 | Robert A. Breyer | Director | Sell | 2,000 | $60.00 | $120,000.00 | 41,156 | |
| 9/23/2015 | Shane Cooke | insider | Sell | 18,000 | $67.09 | $1,207,620.00 | 40,640 | |
| 9/17/2015 | Michael J. Landine | SVP | Sell | 10,000 | $71.20 | $712,000.00 | 138,680 | |
| 9/17/2015 | Richard F. Pops | CEO | Sell | 50,000 | $71.27 | $3,563,500.00 | 542,917 | |
| 9/15/2015 | James M. Frates | CFO | Sell | 20,000 | $71.10 | $1,422,000.00 | 48,713 | |
| 9/10/2015 | Michael J. Landine | SVP | Sell | 10,000 | $67.61 | $676,100.00 | 138,680 | |
| 9/10/2015 | Richard F. Pops | CEO | Sell | 50,000 | $67.57 | $3,378,500.00 | 542,917 | |
| 9/1/2015 | Robert A Breyer | Director | Sell | 2,000 | $61.43 | $122,860.00 | 43,156 | |
| 8/24/2015 | Shane Cooke | insider | Sell | 18,000 | $57.65 | $1,037,700.00 | 40,640 | |
| 7/23/2015 | Shane Cooke | Insider | Sell | 18,000 | $69.79 | $1,256,220.00 | | |
| 7/20/2015 | Gordon G Pugh | COO | Sell | 18,750 | $70.10 | $1,314,375.00 | | |
| 7/14/2015 | James M Frates | CFO | Sell | 20,000 | $65.79 | $1,315,800.00 | | |
| 7/1/2015 | Gordon G Pugh | COO | Sell | 13,750 | $65.13 | $895,537.50 | | |
| 7/1/2015 | Robert A Breyer | Director | Sell | 2,000 | $64.90 | $129,800.00 | | |
| 6/23/2015 | Shane Cooke | Insider | Sell | 18,000 | $66.84 | $1,203,120.00 | | |
| 6/17/2015 | Paul J Mitchell | Director | Sell | 15,500 | $65.10 | $1,009,050.00 | | |
| 6/16/2015 | Gordon G Pugh | COO | Sell | 32,977 | $63.11 | $2,081,178.47 | | |
| 6/16/2015 | James M Frates | CFO | Sell | 10,000 | $58.63 | $586,300.00 | | |
| 6/1/2015 | Paul J Mitchell | Director | Sell | 1,500 | $60.78 | $91,170.00 | | |
| 6/1/2015 | Rebecca Peterson | SVP | Sell | 21,983 | $60.05 | $1,320,079.15 | | |
| 5/26/2015 | Rebecca Peterson | SVP | Sell | 1,322 | $60.49 | $79,967.78 | | |
| 5/26/2015 | Shane Cooke | Insider | Sell | 18,000 | $60.31 | $1,085,580.00 | | |
| 5/22/2015 | Rebecca Peterson | SVP | Sell | 28,558 | $61.71 | $1,762,314.18 | | |
| 5/12/2015 | James M Frates | CFO | Sell | 10,000 | $59.34 | $593,400.00 | | |
| 5/4/2015 | Robert A Breyer | Director | Sell | 2,000 | $60.00 | $120,000.00 | | |
| 5/1/2015 | Paul J Mitchell | Director | Sell | 1,500 | $55.79 | $83,685.00 | | |
| 4/23/2015 | Shane Cooke | Insider | Sell | 18,000 | $62.55 | $1,125,900.00 | | |
| 4/21/2015 | Elliot Ehrich | CMO | Sell | 25,000 | $62.39 | $1,559,750.00 | | |
| 4/15/2015 | Gordon G Pugh | COO | Sell | 13,750 | $63.21 | $869,137.50 | | |
| 4/15/2015 | James M Frates | CFO | Sell | 10,000 | $62.42 | $624,200.00 | | |
| 4/15/2015 | Paul J Mitchell | Director | Sell | 1,500 | $62.71 | $94,065.00 | | |
| 4/1/2015 | Robert A Breyer | Director | Sell | 5,000 | $61.22 | $306,100.00 | | |
| 3/23/2015 | Shane Cooke | Insider | Sell | 18,000 | $65.33 | $1,175,940.00 | | |
| 3/16/2015 | Elliot Ehrich | CMO | Sell | 18,000 | $66.81 | $1,202,580.00 | | |
| 3/10/2015 | James M Frates | CFO | Sell | 10,000 | $66.25 | $662,500.00 | | |
| 3/5/2015 | Rebecca Peterson | SVP | Sell | 17,737 | $71.37 | $1,265,889.69 | | |
| 3/2/2015 | Gordon G Pugh | COO | Sell | 15,000 | $71.39 | $1,070,850.00 | | |
| 3/2/2015 | Robert A Breyer | Director | Sell | 5,000 | $70.86 | $354,300.00 | | |
| 2/23/2015 | Shane Cooke | Insider | Sell | 18,000 | $74.29 | $1,337,220.00 | | |
| 2/17/2015 | Elliot Ehrich | CMO | Sell | 18,000 | $70.87 | $1,275,660.00 | | |
| 2/3/2015 | James M Frates | CFO | Sell | 10,000 | $70.83 | $708,300.00 | | |
| 2/2/2015 | Gordon G Pugh | COO | Sell | 15,000 | $72.01 | $1,080,150.00 | | |
| 2/2/2015 | Robert A Breyer | Director | Sell | 5,000 | $72.91 | $364,550.00 | | |
| 1/26/2015 | Gordon G Pugh | COO | Sell | 15,000 | $70.02 | $1,050,300.00 | | |
| 1/23/2015 | Shane Cooke | Insider | Sell | 118,000 | $69.13 | $8,157,340.00 | | |
| 1/16/2015 | Floyd E Bloom | Director | Sell | 20,000 | $67.12 | $1,342,400.00 | | |
| 1/15/2015 | Elliot Ehrich | CMO | Sell | 18,375 | $66.45 | $1,221,018.75 | | |
| 1/15/2015 | James M Frates | CFO | Sell | 10,000 | $66.86 | $668,600.00 | | |
| 1/7/2015 | Kathryn L Biberstein | SVP | Sell | 28,374 | $65.00 | $1,844,310.00 | | |
| 1/2/2015 | Robert A Breyer | Director | Sell | 5,000 | $58.57 | $292,850.00 | | |
| 12/11/2014 | Richard F Pops | CEO | Sell | 100,000 | $56.04 | $5,604,000.00 | | |
| 12/10/2014 | James M Frates | CFO | Sell | 18,870 | $56.07 | $1,058,040.90 | | |
| 12/9/2014 | Michael J Landine | SVP | Sell | 18,000 | $56.82 | $1,022,760.00 | | |
| 12/5/2014 | Kathryn L Biberstein | SVP | Sell | 15,433 | $57.61 | $889,095.13 | | |
| 12/1/2014 | Robert A Breyer | Director | Sell | 5,000 | $54.64 | $273,200.00 | | |
| 11/19/2014 | James M Frates | CFO | Sell | 8,000 | $53.86 | $430,880.00 | | |
| 11/13/2014 | Richard F Pops | CEO | Sell | 100,000 | $52.87 | $5,287,000.00 | | |
| 11/7/2014 | James M Frates | CFO | Sell | 13,303 | $49.98 | $664,883.94 | | |
| 11/6/2014 | Kathryn L Biberstein | SVP | Sell | 20,000 | $50.54 | $1,010,800.00 | | |
| 11/3/2014 | Robert A Breyer | Director | Sell | 5,000 | $50.05 | $250,250.00 | | |
| 10/23/2014 | Gordon G Pugh | COO | Sell | 14,577 | $45.00 | $655,965.00 | | |
| 10/8/2014 | James M Frates | CFO | Sell | 16,000 | $41.00 | $656,000.00 | | |
| 10/1/2014 | Robert A Breyer | Director | Sell | 5,000 | $42.59 | $212,950.00 | | |
| 9/24/2014 | James M Frates | CFO | Sell | 16,000 | $45.29 | $724,640.00 | | |
| 9/18/2014 | Michael J Landine | SVP | Sell | 15,000 | $45.60 | $684,000.00 | | |
| 9/17/2014 | Gordon G Pugh | COO | Sell | 14,900 | $45.04 | $671,096.00 | | |
| 9/17/2014 | Richard F Pops | CEO | Sell | 50,000 | $44.89 | $2,244,500.00 | | |
| 9/10/2014 | James M Frates | CFO | Sell | 16,000 | $43.18 | $690,880.00 | | |
| 9/2/2014 | Gordon G Pugh | COO | Sell | 1,100 | $45.08 | $49,588.00 | | |
| 9/2/2014 | Robert A Breyer | Director | Sell | 5,000 | $45.12 | $225,600.00 | | |
| 8/27/2014 | James M Frates | CFO | Sell | 16,000 | $45.08 | $721,280.00 | | |
| 8/26/2014 | Gordon G Pugh | COO | Sell | 16,000 | $45.00 | $720,000.00 | | |
| 8/13/2014 | James M Frates | CFO | Sell | 15,000 | $41.37 | $620,550.00 | | |
| 8/11/2014 | Elliot Ehrich | CMO | Sell | 16,667 | $41.65 | $694,180.55 | | |
| 8/4/2014 | Gordon G Pugh | COO | Sell | 23,250 | $43.20 | $1,004,400.00 | | |
| 8/1/2014 | Robert A Breyer | Director | Sell | 5,000 | $42.53 | $212,650.00 | | |
| 7/16/2014 | James M Frates | CFO | Sell | 8,000 | $46.50 | $372,000.00 | | |
| 7/9/2014 | Elliot Ehrich | CMO | Sell | 16,667 | $47.41 | $790,182.47 | | |
| 7/9/2014 | James M Frates | CFO | Sell | 7,000 | $47.41 | $331,870.00 | | |
| 7/3/2014 | Michael J Landine | SVP | Sell | 7,000 | $51.31 | $359,170.00 | | |
| 7/2/2014 | Richard F Pops | CEO | Sell | 50,000 | $51.69 | $2,584,500.00 | | |
| 7/1/2014 | Gordon G Pugh | COO | Sell | 16,000 | $46.49 | $743,840.00 | | |
| 7/1/2014 | Robert A Breyer | Director | Sell | 5,000 | $50.57 | $252,850.00 | | |
| 6/26/2014 | Michael J Landine | SVP | Sell | 10,000 | $49.92 | $499,200.00 | | |
| 6/25/2014 | James M Frates | CFO | Sell | 7,000 | $50.22 | $351,540.00 | | |
| 6/25/2014 | Richard F Pops | CEO | Sell | 50,000 | $49.87 | $2,493,500.00 | | |
| 6/20/2014 | Paul J Mitchell | Director | Sell | 17,000 | $50.00 | $850,000.00 | | |
| 6/19/2014 | Elliot Ehrich | CMO | Sell | 17,282 | $47.10 | $813,982.20 | | |
| 6/19/2014 | Michael J Landine | SVP | Sell | 10,000 | $47.01 | $470,100.00 | | |
| 6/18/2014 | Richard F Pops | CEO | Sell | 50,000 | $46.72 | $2,336,000.00 | | |
| 6/17/2014 | Kathryn L Biberstein | SVP | Sell | 8,400 | $47.41 | $398,244.00 | | |
| 6/11/2014 | James M Frates | CFO | Sell | 7,000 | $47.72 | $334,040.00 | | |
| 6/9/2014 | Elliot Ehrich | CMO | Sell | 16,667 | $48.15 | $802,516.05 | | |
| 6/2/2014 | Gordon G Pugh | COO | Sell | 16,000 | $45.34 | $725,440.00 | | |
| 6/2/2014 | Robert A Breyer | Director | Sell | 5,000 | $45.18 | $225,900.00 | | |
| 5/30/2014 | Rebecca Peterson | SVP | Sell | 21,981 | $45.86 | $1,008,048.66 | | |
| 5/23/2014 | Rebecca Peterson | SVP | Sell | 1,321 | $45.08 | $59,550.68 | | |
| 5/22/2014 | Elliot Ehrich | CMO | Sell | 2,378 | $44.49 | $105,797.22 | 20,992 | |
| 5/22/2014 | Gordon Pugh | COO | Sell | 15,700 | $45.25 | $710,425.00 | 54,192 | |
| 5/22/2014 | Rebecca Peterson | SVP | Sell | 19,807 | $44.02 | $871,904.14 | 1,321 | |
| 5/21/2014 | Elliot Ehrich | CMO | Sell | 1,981 | $44.00 | $87,164.00 | 23,370 | |
| 5/21/2014 | James Frates | CFO | Sell | 7,000 | $44.30 | $310,100.00 | 42,904 | |
| 5/20/2014 | Rebecca Peterson | SVP | Sell | 20,307 | $44.05 | $894,523.35 | | |
| 5/19/2014 | Elliot Ehrich | CMO | Sell | 2,206 | $43.55 | $96,071.30 | 20,992 | |
| 5/8/2014 | Floyd Bloom | Director | Sell | 10,000 | $46.16 | $461,600.00 | 90,281 | |
| 5/5/2014 | Robert Breyer | Director | Sell | 5,000 | $46.72 | $233,600.00 | 53,756 | |
| 5/1/2014 | Paul Mitchell | Director | Sell | 1,000 | $45.90 | $45,900.00 | 8,000 | |
| 4/9/2014 | James Frates | CFO | Sell | 7,000 | $42.91 | $300,370.00 | 36,644 | |
| 4/1/2014 | Paul Mitchell | Director | Sell | 1,500 | $44.14 | $66,210.00 | 8,000 | |
| 3/19/2014 | James Frates | CFO | Sell | 7,000 | $46.84 | $327,880.00 | 36,644 | |
| 3/11/2014 | Wendy Dixon | Director | Buy | 1,600 | $47.37 | $75,792.00 | 1,600 | |
| 3/5/2014 | James Frates | CFO | Sell | 7,000 | $47.78 | $334,460.00 | 93,644 | |
| 2/18/2014 | Elliot Ehrich | CMO | Sell | 7,718 | $52.45 | $404,809.10 | 16,579 | |
| 2/3/2014 | Paul Mitchell | Director | Sell | 1,500 | $48.15 | $72,225.00 | 8,000 | |
| 1/21/2014 | Elliot Ehrich | CMO | Sell | 7,718 | $48.61 | $375,171.98 | 16,579 | |
| 1/16/2014 | Elliot Ehrich | CMO | Sell | 14,555 | $47.35 | $689,179.25 | 16,579 | |
| 1/16/2014 | Gordon Pugh | COO | Sell | 30,000 | $47.16 | $1,414,800.00 | 48,301 | |
| 1/16/2014 | James Frates | CFO | Sell | 7,000 | $47.40 | $331,800.00 | 93,644 | |
(Data available from 1/1/2013 forward)
Alkermes (NASDAQ ALKS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Alkermes (ALKS) option implied volatility elevated into EPS and outlook
www.streetinsider.com - April 25 at 4:50 PM |
 | Alkermes' ALKS 5461 Moves Closer To Commercialization
seekingalpha.com - April 24 at 4:55 PM |
 | Is Alkermes' Promising Depression Drug Back On Track?
www.fool.com - April 24 at 9:06 AM |
 | Is Alkermes' Promising Depression Drug Back On Track?
finance.yahoo.com - April 23 at 4:38 PM |
| Johnson & Johnson's First-Quarter 2018 Earnings Review
finance.yahoo.com - April 22 at 5:37 PM |
 | Alkermes (ALKS) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 20 at 11:52 AM |
| Alkermes Gets Ability To Refile NDA, But All Is Still Not Rosy
seekingalpha.com - April 19 at 4:52 PM |
| Alkermes to Host Conference Call to Discuss First Quarter 2018 Financial Results
finance.yahoo.com - April 19 at 4:52 PM |
| Alkermes Plc (ALKS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 19 at 10:15 AM |
| Alkermes (ALKS) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - April 18 at 12:50 PM |
| Wired News – FDA Accepts NDA Review for Alkermes’ ALKS 5461 for Treatment of Major Depressive Disorder
finance.yahoo.com - April 18 at 9:12 AM |
| Alkermes (ALKS) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 18 at 3:44 AM |
| Biotech Analysis Central Pharma News: Merck's Keytruda Breakthrough, Bristol Myers And JNJ Team Up, Alkermes ...
seekingalpha.com - April 17 at 5:08 PM |
| J&J cost cutting plan may pressure suppliers - Bloomberg
seekingalpha.com - April 17 at 9:31 AM |
 | Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round
www.thestreet.com - April 17 at 9:31 AM |
| Company News For Apr 17, 2018
finance.yahoo.com - April 17 at 9:31 AM |
| Zacks: Analysts Expect Alkermes Plc (ALKS) Will Post Quarterly Sales of $221.82 Million
www.americanbankingnews.com - April 17 at 5:06 AM |
 | Thinking about buying stock in Alkermes, Bank of America, CVS Health Corp, The Goldman Sachs Group and Tesla ...
www.prnewswire.com - April 16 at 4:39 PM |
| Is It Time to Give Up on Alkermes?
finance.yahoo.com - April 16 at 4:39 PM |
| Alkermes Wins Quick Reversal From FDA on Antidepressant Drug
finance.yahoo.com - April 16 at 4:39 PM |
| Credit Suisse Group Analysts Give Alkermes (ALKS) a $63.00 Price Target
www.americanbankingnews.com - April 16 at 3:37 PM |
| Alkermes Announces FDA Acceptance for Review of New Drug Application for ALKS 5461 for the Adjunctive Treatment ...
www.prnewswire.com - April 16 at 9:04 AM |
| Alkermes's stock soars after FDA accepts NDA review, 2 weeks after refusing
finance.yahoo.com - April 16 at 9:03 AM |
| Alkermes Announces FDA Acceptance for Review of New Drug Application for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder
finance.yahoo.com - April 16 at 9:03 AM |
| Alkermes (ALKS) Cut to Sell at ValuEngine
www.americanbankingnews.com - April 15 at 7:48 PM |
| -$0.08 Earnings Per Share Expected for Alkermes Plc (ALKS) This Quarter
www.americanbankingnews.com - April 15 at 1:17 AM |
| Alkermes (ALKS) Cut to Sell at BidaskClub
www.americanbankingnews.com - April 15 at 12:36 AM |
| Alkermes (ALKS) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 14 at 10:19 AM |
| BidaskClub Lowers Alkermes (ALKS) to Strong Sell
www.americanbankingnews.com - April 11 at 10:42 PM |
| BidaskClub Lowers Alkermes (ALKS) to Hold
www.americanbankingnews.com - April 11 at 11:30 AM |
| Alkermes Has Some Decisions to Make
finance.yahoo.com - April 11 at 9:45 AM |
| Alkermes (ALKS) Downgraded by Barclays
www.americanbankingnews.com - April 7 at 10:53 AM |
| Alkermes Receives Refusal To File Letter From The FDA, Is There Any Hope?
seekingalpha.com - April 6 at 4:56 PM |
| ValuEngine Downgrades Alkermes (ALKS) to Sell
www.americanbankingnews.com - April 6 at 11:39 AM |
 | FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus
www.zacks.com - April 5 at 9:23 AM |
| Alkermes' Bad News Could Be Good News for Johnson & Johnson
www.fool.com - April 5 at 9:23 AM |
| Alkermes Plc (ALKS) Director Sells $46,750.00 in Stock
www.americanbankingnews.com - April 4 at 11:37 PM |
| Alkermes Sees Unusually Large Options Volume (ALKS)
www.americanbankingnews.com - April 4 at 6:52 AM |
| Alkermes (ALKS) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 3 at 8:10 PM |
| Biotech Analysis Central Pharma News: Takeda's Potential Bid, Alkermes Setback, MediciNova Impresses
seekingalpha.com - April 3 at 4:44 PM |
| Alkermes Sinks as FDA Refuses Depression Drug Review
finance.yahoo.com - April 3 at 4:44 PM |
| JPMorgan Chase Analysts Give Alkermes (ALKS) a $63.00 Price Target
www.americanbankingnews.com - April 3 at 10:37 AM |
| Free Research Reports on These Drug Delivery Stocks -- Alkermes, PetMed Express, Valeant Pharma, and Adamis ...
www.prnewswire.com - April 3 at 9:26 AM |
 | Drugmaker Alkermes confirms expansion, hiring plans in Waltham
www.bizjournals.com - April 3 at 9:26 AM |
| Alkermes (ALKS) PT Lowered to $55 at Cowen
www.streetinsider.com - April 2 at 4:43 PM |
 | Brainstorm Health: DNA Testing Accuracy, Marijuana Laws and the Opioid Crisis, Alkermes Stock
fortune.com - April 2 at 4:43 PM |
| Here's Why Alkermes plc and Intra-Cellular Therapies, Inc. Are Crashing Today
www.fool.com - April 2 at 4:43 PM |
| Alkermes Plunges After FDA Refuses To Review Depression Drug
finance.yahoo.com - April 2 at 4:43 PM |
| Cowen Cuts Alkermes (ALKS) Price Target to $55.00
www.americanbankingnews.com - April 2 at 4:16 PM |
| Alkermes (ALKS) Given Outperform Rating at Credit Suisse Group
www.americanbankingnews.com - April 2 at 1:30 PM |
Alkermes (NASDAQ:ALKS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Alkermes (NASDAQ:ALKS) Income Statement, Balance Sheet and Cash Flow Statement
Alkermes (NASDAQ ALKS) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
